An Indian-origin professor’s Oxford-based company announced on Tuesday that its Indian partner, Serum Institute of India (SIIPL), has begun testing a novel virus-like particle (VLP) vaccine targeting Kovid-19. , Which has the potential to offer a new way to fight the epidemic.
Prof. Sumi Biswas, CEO and co-founder of SpyBiotech – an Oxford University spinoff company with a novel vaccine platform targeting infectious diseases, cancer and chronic diseases, said the first topics were a phase / II trial Has been planted in.
SpyBiotech stated that it has signed an exclusive global licensing agreement with SIIPL for the development of the vaccine as part of a study initiated in Australia.
“Combining SpyBiotech’s unique platform technology with VLP and its extensive manufacturing expertise, Serum’s extensive expertise provides us with the tools to produce the large amounts of supplements needed to support the global fight against Covid-19. Do, ”said Biswas. , Is a Kolkata-born immunologist.
“For Spybiotech, this is an opportunity to provide an instant proof point for our platform technology, along with other candidates we are moving into clinical development. Many vaccines to make our technology a plug and display vaccine Can be linked with distribution platforms. It is important to produce vaccines quickly and safely, “she said.
Mr Vishwas moved to the UK in 2005 to study microbiology at the University of Bangalore and became an associate professor of vaccine at the Jenner Institute at the University of Oxford, which is currently working on another Kovid-19 vaccine candidate.
Spybiotech says its vaccine candidate uses its “proprietary” spycatcher / spyTag protein “superglue” technique to display coronovirus spike proteins on the surface of the hepatitis B surface antigen (HBsAg) VLP, a human. Contains a licensed vaccine with “excellent safety and immunogenicity data”. And which are currently manufactured for billions of doses. The receptor-binding domain of the coronovirus spike protein is demonstrated on VLPs, leveraging the properties of the platform to induce a potent immune response.
SIIPL CEO Adar Poonawala said, “We are very excited about collaborating with SpyBiotech to work on this novel vaccine for Covid-19.”
“This new technology has the potential to be a powerful new approach to combat the epidemic. SIIPL looks forward to working with Spybiotech to advance this candidate through clinical development.”
SpyCatcher / SpyTag is a platform technology that allows antigens to be displayed on VLPs with covalent, irreversible binding in a highly stable and effective manner with specific orientation / epitope presentation and high density. The technology can be used for exceptionally wide applications in vaccine development and has established proof of concept data in viral, bacterial, parasitic diseases and chronic diseases and cancer.
SpyBiotech stated that it has exclusive rights from the University of Oxford to implement, commercialize and sub-license “plug and display” technology for vaccine development.
“Finding a safe and effective vaccine against SARS-CoV-2 [Covid-19] “The virus is one of the biggest scientific challenges of our time,” said Lachlan Mackinnon, Oxford Sciences’ innovation principal and chairman of SpyBiotech.
“Mixing the benefits of the Spybiotech Protein” provides the potential for an effective, safe COVID-19 vaccine with known safety and immunogenicity techniques such as the Serum Institute’s Hepatitis B Surface Antigen Virus, which can be mass-produced. ” said.
Through the latest agreement, he said that Spybiotech’s technology could be added to the growing weaponry that is being developed against the disease.
“We hope that the development program will help validate the broad potential of the technology, which will be used to target other infectious diseases and cancers in the future,” he said.
SpyBiotech dropped out of Oxford University in 2017 and its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way that reduces delivery risk and enhances immunogenicity and efficacy.
The company said it was supported by high-quality investors including Oxford Science Innovation (OSI), a capital investor for Oxford University, and GV (formerly Google Ventures) and has raised £ 15 million in funds so far.